Renal news roundup from AKF

Boehringer Ingelheim's transient receptor potential canonical 6 (TRPC6) inhibitor apecotrep, initially developed for COVID-19, has shown positive results in a Phase 2 trial for treating the rare kidney disease focal segmental glomerulosclerosis. Published in The Lancet, the ...

Outset Medical has received FDA 510(k) clearance for its next-generation Tablo hemodialysis platform, making it the first such system to incorporate the agency's latest cybersecurity guidance. MassDevice (Boston) (1/27)

Researchers have discovered a possible link between chronic kidney disease and heart failure, finding that diseased kidneys release toxic extracellular vesicles that can harm the heart, with supporting studies conducted with mice demonstrating similar cardiac effects. The researc...

CalciMedica has discontinued a Phase 2 trial of its calcium release-activated calcium channel inhibitor Auxora for patients with acute kidney injury (AKI) due to a safety concern identified by an independent data monitoring committee. CEO Rachel Leheny said the company will revie...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with a lower five-year risk of chronic kidney disease (CKD) and AKI compared with glucagon-like peptide-1 (GLP-1) receptor agonists in adults with type 2 diabetes (T2D), according to a study published in JAMA Intern...

Women with preeclampsia during pregnancy face higher risks of chronic kidney disease, according to a study published in the Journal of the American Society of Nephrology. Researchers found that albuminuria and low estimated glomerular filtration rates were associated with CKD ris...

Research shows that eating a vegetarian or vegan diet may lower the risk of heart disease, certain cancers and death. A study published in the Canadian Medical Association Journal associated following the EAT-Lancet planetary diet, which focuses on fruits, vegetables and legumes,...

Adolescents and young adults with glomerular disease display distinct clinical profiles, differing significantly from pediatric and adult populations, according to a study in Kidney360. The study highlights that minimal change disease is common in pediatric patients, while IgA ne...

The FDA has extended the review timeline for Travere Therapeutics' supplemental new drug application for FILSPARI or sparsentan to treat focal segmental glomerulosclerosis, with a new target action date of April 13. The extension comes after the company submitted additional ...